Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia reported positive Phase 1b/2a data for EP-104GI, showing meaningful reductions in both odynophagia and dysphagia symptoms in EoE patients out to 52 weeks. The analysis of Cohorts 7-9 found that the proportion of patients with moderate to severe odynophagia dropped from 62% at baseline to 25% at weeks 24-52, with zero patients reporting severe symptoms at those timepoints.
Key figures
- Drug Name
- EP-104GI
- Phase Of Trial
- Phase 1b/2a
- Safety saes
- 0
- Injection sites
- >2000
- Patients treated total
- >130
- Dysphagia reduction severe
- 31% at baseline to 0% at 24 and 52 weeks
- Odynophagia reduction severe
- 23% at baseline to 0% at 24 and 52 weeks
- Dysphagia reduction mod severe
- 77% at baseline to 25% at 24 and 52 weeks
- Odynophagia reduction mod severe
- 62% at baseline to 25% at 24-52 weeks
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.